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hyperlipidemia based on the standardized interview conducted by the National
Center for Health Statistics (NCHS) among adults  18 years. Descriptive statistics
and multivariate logistic regression were used to determine predictors having the
combined diagnosis including the following independent variables: gender, age,
race, ethnicity, urban/rural status and smoking status. Statistical analysis was
performed using SAS 9.2. RESULTS: The total sample included 33,994 individuals
and the combined diagnosis of hypertension and hyperlipidemia was reported in
4.49% of the sample. Of these, 61.51% were females and 41% were aged between
60-75 years. Most (73.25%) of these patients were whites and more than half
(54.75%) reported to have smoked at least 100 cigarettes in their lifetime, while
34.01% were current smokers. In the multivariate model, significant predictors of
the combined diagnosis included female gender (OR 0.689; 95% CI 0.594 – 0.798;
p.0001), age 60-75 years vs. younger age (OR1.627; 95% CI1.296 – 2.042;
p.0001),MexicanAmerican race vs. non-hispanics (OR 0.611; 95%CI 0.49 – 0.76;
p.0007) and current smokers. (OR1.374; 95% CI1.08-1.75; p.0001).
CONCLUSIONS: Our findings emphasize the importance of developing effective
intervention strategies that help smokers quit and may reduce prevalence of hy-
perlipidemia with hypertension along with the accompanying cardiovascular risk.
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OBJECTIVES: Diabetes prevalence has grown rapidly in China. As the largest epi-
demiology and clinical outcomes assessment program, China Cardiometabolic
Registries (CCMR), has been designed to establish systemic evaluation on disease
progression and influencing factors. The Nationwide Assessment of CVD Risk Fac-
tors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients with type
2 Diabetes (T2D) (CCMR-3B) was one of the CCMR studies and was conducted to
assess the clinical outcomes of current treatment patterns.METHODS: This was a
cross sectional, observational study. Patients were recruited from community (tier
1), regional (tier 2), and teaching hospitals (tier 3) from all 6 major geographic
regions in China, by cardiologists, nephrologists and endocrinologist, and internal
medicine. RESULTS: A total of 5099 T2D patients was included for this analysis.
Across all hospitals, 55% and 34% of the patients had hypertension (HTN) or dis-
lipidemia (DYLP), respectively, while 33% had neither. No difference was found
between hospitals regarding the proportion of patients reaching target control
(HbA1C7.0%, BP130/80 mmHg, LDL2.6 mmol/L) in those who also have HTN or
DYLP (ranging from 4.4 % to 6.6% for the HTN group and 6.9% to8.0% for the DYLP
group). However a trend toward a better HbA1C control in patients without HTN or
DYLP (diabetes only) in larger hospitalswas seen (10.7%, 11.2%, 15.4% in tier 1, 2 and
3 hospitals, respectively). A trend toward more use of multiple oral anti-diabetic
drugs and insulin was also seen in larger hospitals. CONCLUSIONS: Better HbA1c
control seen in larger hospitals was associated with more aggressive use of antidi-
abetic treatment. The control of cardiovascular risk factors, blood glucose, blood
pressure, and blood lipid, in diabetes patients with HTN or DYLP remains to be
challenging in all hospital settings.
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PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE
MYOCARDIAL INFARCTION: AN ANALYSIS OF THE MEDICARE 5% NATIONAL
SAMPLE DATA 2006-2007
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OBJECTIVES: To study the predictors of beta-blocker therapy discontinuation
among post myocardial infarction (MI) patients enrolled in Medicare. METHODS:
This is a retrospective cohort study utilizing a Medicare 5% national sample claims
data for 2006-2007. Medicare beneficiaries with continuous Part A, B, and D enroll-
ment in 20062007, and who were hospitalized for an acute MI in the first six
months of 2006 were identified using a validated algorithm, requiring a hospital-
ization episode 3 and 180 days with an ICD-9-CM of 410.x1 as principal or sec-
ondary diagnosis. Post-MI patientswith a filled prescription for beta-blockerwithin
90 days of discharge were followed until the end of the study period. Time to
discontinuation was defined as days from initiation of therapy to a gap of90 days
in therapy. Survival curves were modeled using the Kaplan-Meier technique, and
potential predictors of therapy discontinuation, including demographic character-
istics, comorbid conditions and concomitant medications were estimated using
Cox proportional hazards regression. RESULTS: Of the 2,505 subjects who met our
inclusion criteria, 65.1% were females, 83.3% were Caucasian, mean age 78.6 (8.2)
years. About 15% of them discontinued therapywithin sixmonths and around 35%
discontinued within a year. Males weremore likely to discontinue therapy as com-
pared to females (HR1.166; [1.020-1.334]; p0.0245) and Caucasians (HR0.674;
[0.557-0.815]; p0.0001) were less likely to discontinue therapy compared to Afri-
can Americans. The results of Cox proportional hazardsmodel shows that diabetes
(HR1.224; [1.069-1.402]; p0.0035), dyslipidemia (HR0.675; [0.565-0.807];
p.0001), CHF (HR1.234; [1.03-1.478]; p0.0223), cerebrovascular disease
(HR1.206; [1.057-1.376]; p0.0054) and COPD (HR1.209; [1.061-1.377]; p0.0043)
were significant predictors of time to discontinuation. Patients on concomitant
statin treatment were less likely to discontinue beta-blocker therapy (HR0.774;
[0.667-0.899]; p0.0008). CONCLUSIONS: Many patients initiating beta-blocker
therapy post MI fail to consistently remain on the treatment. Several demographic
characteristics and comorbid conditions are associated with this behavior.
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FAILURE MEDICARE BENEFICIARIES WITH AND WITHOUT DEPRESSION
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OBJECTIVES: Adherence to chronic heart failure (CHF) medications decreases pre-
ventable hospitalizations. Nevertheless, CHF rarely occurs without concomitant
conditions. We sought to: 1) evaluate impact of comorbid depression on CHFmed-
ication use and adherence among Medicare beneficiaries with CHF(CHF_MED-
_BEN); 2) examine relationships between CHF medication adherence and out-
comes; and 3) determine if depression modifies this relationship. METHODS: We
employed a cross-sectional design of 2006-2007 CMS Medicare Chronic Condition
Warehouse (CCW) database. Sample was restricted to CHF_MED_BEN with Medi-
care A,B and D to observe all prescription and medical claims. We classified indi-
viduals with CHF and depression if theymet the CCWdefinitions. Adherencemea-
sures included any use (binary) and medication possession ratio (MPR) for
evidence-based CHF medications (EBM). Multivariable analyses included an inter-
action term to test effect modification of depression on the relationship between
EBM adherence and number of hospitalizations. Relative rates of hospitalization
are reported with 95%CI. RESULTS: A total of 151,924 CHF_MED_BENmet inclusion
criteria. Mean agewas 75.9/-12.0 years; 68%were female. 25%had depression and
they were significantly younger(74.5 vs. 76.3 years,p0.001) and more likely to be
female(75% vs. 66%,p0.001) compared to non-depressed CHF_MED_BEN. A signif-
icantly lower proportion of depressed CHF_MED_BEN received EBM (75% vs.
79%,p0.001), compared to non-depressed CHF_MED_BEN.MedianMPRwas 0.92 in
both groups. A higher proportion of depressed CHF_MED_BEN was hospitalized
(76% vs. 63%,p0.001) and re-hospitalized (40.5% vs. 38.6%,p0.001) compared to
non-depressed CHF_MED_BEN. In multivariable models, depression modified the
effect of adherence on hospitalizations (interaction term p0.001): compared to
high adherence (MPR0.9), poor adherence (MPR0.5) was associated with a 24%
(95%CI 1.20-1.28) increased hospitalization rate among non-depressed CHF_MED-
_BEN and a 45% (95%CI 1.37-1.54) increased hospitalization rate among depressed
CHF_MED_BEN. CONCLUSIONS: Depression was not associated with poor EBM ad-
herence among CHF_MED_BEN. Poor EBM adherence was associated with in-
creased hospitalization in both depressed and non-depressed groups, with a
greater effect among depressed CHF_MED_BEN.
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OBJECTIVES: To compare the performance of pulmonary arterial hypertension
(PAH) drug classes based on the risk of mortality reported in clinical trials, and
inform a revised PAH treatment algorithm. METHODS: The study used Bayesian
Analysis Using Gibbs Sampling in Windows (WinBUGS) and Monte Carlo Simula-
tions to conduct a multiple treatment comparison of placebo and three PAH drug
classes; prostanoids (Treprostinil & Iloprost), endothelin-receptor antagonists
(Bosentan, Sitaxsentan, & Ambrisentan), and phosphodiesterase (sildenafil). Direct
and indirect pairwise odds ratios (OR) were obtained. Published PAH studies
through 2010 were identified from MEDLINE (PubMed) database and an extended
manual search was also conducted based on references from identified studies.
Inclusion was restricted to randomized controlled trials lasting at least 12 weeks
and at most 16 weeks, with subjects having either idiopathic or associated PAH,
and studies that reported mortality as an endpoint. Studies that compared combi-
nations of drugs were excluded from the analysis. Results are reported in OR with
95% credible intervals. RESULTS: In total 8 studies (20 treatment arms, 2,015 sub-
jects enrolled) were included in the analysis. 2 studies were 3-arm trials and 1 was
a 4-arm trial.With placebo as the reference class, the OR ofmortalitywas 1.00 (0.06,
4.20) for prostanoids; 1.14 (0.15, 4.69) for endothelin-receptor antagonists and 0.62
(0.05, 2.83) for phosphodiesterase. Using prostanoids as the reference class, the OR
of mortality was 4.28 (0.10, 23.10) for endothelin-receptor antagonists and 2.40
(0.04, 12.66) for phosphodiesterase. Using endothelin-receptor antagonists as the
reference class, the OR of mortality was 1.11 (0.04, 5.55) for phosphodiesterase.
None of the ORs were statistically significant. CONCLUSIONS: Based on the risk of
mortality reported in clinical trials, there is no statistically significant difference
among PAH drug classes. Including more studies/drugs and the use of different
PAH outcomes could inform a more detailed comparison.
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OBJECTIVES: To evaluate the association between persistent use of statins and the
risk of acute cardiovascular events among primary prevention patients in commu-
nity settings. METHODS: A population-based retrospective cohort among 171,846
adults aged 45-75, with no history of any cardiovascular disease, who began statin
therapy between 1998 and 2009. Proportion of days covered (PDC) with statins was
measured by the number of dispensed prescriptions during follow-up period.
Study endpoint was occurrence of a major cardiovascular event, which comprised
myocardial infarction or performance of a cardiac revascularization procedure
RESULTS: The fully adjusted survival analysis indicated a significant negative as-
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sociation between persistence with statins and risk of incident cardiac events. The
most persistent users (PDC  80%) had a hazard ratio of 0.62 (95% confidence
interval: 0.58-0.67) compared to non-persistent users (PDC 20%). Similar results
were found when analyses were limited to patients with more than 5 years of
follow up. An interaction analysis between persistence and other factors detected
a stronger risk reduction among diabetic males. CONCLUSIONS: This large and
unselected community-based study supports the results of several randomized
controlled trials regarding the beneficial effect of persistent statin therapy against
cardiac events among primary prevention patients.
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OBJECTIVES: Healthcare Effectiveness Data and Information Set (HEDIS) defines
controlled hypertension as systolic/diastolic BP (SBP/DBP) 130/80 mm Hg for pa-
tients with essential hypertension and diabetes. We estimated the percentage of
diabetes patients with uncontrolled essential hypertension who would reach SBP
goals with the angiotensin II receptor blockers (ARBs) azilsartan medoxomil, val-
sartan, and olmesartan medoxomil. METHODS: A Monte Carlo simulation model
was created to estimate the number of patients with hypertension (SBP 130 mm
Hg) and diabetes who would achieve SBP goal when treated with azilsartan med-
oxomil, valsartan, or olmesartan medoxomil for 12 months. A cohort of 100,000
hypothetical diabetes patients with uncontrolled hypertension was created from
NHANES 1999–2006 and assigned a baseline SBP. Follow-up SBPswere generated by
randomly sampling from themean and SD of the percentage change from baseline
to final visit in sitting office SBPs by using data from the diabetes subpopulation
from the azilsartanmedoxomil clinical trial program.MeanSD relative changes in
SBP were 10.36%10.41, 4.58%11.04, 5.16%11.82% (F-test P.001) for azil-
sartan medoxomil, valsartan,and olmesartan medoxomil, using the pooled effica-
cies across all dosages, respectively. We assessed goal attainment assuming that
adherence was alternatively perfect and that 48% of patients receiving any ARB
would discontinue treatment. RESULTS: Patient characteristics based on NHANES
data were meanSD age 5613 years, 56% male, 23% with prior cardiovascular
disease, baseline SBP 15119mmHg.We estimated that 41.0%of patients receiving
azilsartanmedoxomil would achieve SBP goal vs. 26.8% for valsartan and 28.8% for
olmesartan medoxomil, assuming perfect adherence; accounting for nonadher-
ence, 21.2%, 13.9%, and 14.8% of patients would reach SBP goals, respectively.
CONCLUSIONS:Our findings suggest thatmore diabetes patients treatedwith azil-
sartan medoxomil than with valsartan or olmesartan medoxomil are expected to
reach SBP goal. Further analysis should address whether these differences in SBP
translate into better HEDIS quality scores.
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OBJECTIVES: Low molecular weight heparins (LWMH) are indicated in unstable
angina and non-Q-wave myocardial infacrtion. Even though both agents have
demonstrated safety and at least comparable efficacy to unfractionated heparin
(UH), there have been no head to head trials to assess comparative effectiveness.
Meta analytic techniques were used to perform an indirect statistical comparison
between dalteparin and enoxaparin in patients with unstable coronary artery dis-
ease (UCAD). METHODS: A literature search was conducted from January 1980 to
November 2009 for randomized controlled trials evaluating dalteparin or enoxa-
parin for the prevention of myocardial infarctions (MI) and death in UCAD. Binary
outcomes (e.g. MIs, death) for the LMWH relative to UH were statistically pooled
using a fixed effectsmodel. Using UH as the common control, an indirect statistical
comparison between dalteparin and enoxaparinwas performedusingmeta regres-
sion analysis with active drug (dalteparin or enoxaparin) as the primary indepen-
dent variable. RESULTS: Six UH controlled enoxaparin (n4) and dalteparin (n2)
trials met the inclusion criteria. The meta analysis of all trial data showed that
patients treated with enoxaparin or dalteparin had an 11% relative risk reduction
for MI compared to UH (RR  0.89, p  0.009). This benefit was achieved without a
significant increase in the risk for major bleeding (RR 0.98, p 0.85), thrombocy-
topenia (RR  1.14, p  0.35) or death (RR  0.95, p  0.68). The indirect statistical
comparison was unable to find significant differences between enoxaparin and
dalteparin in terms of MI (p0.67), major bleeds (p0.79), thrombocytopenia
(p0.23) or death (p0.10). CONCLUSIONS:Our findings suggest comparable safety
and efficacy between dalteparin and enoxaparin when used to prevent MI and
death in patients with UCAD. Therefore, treatment decisions should be based on
other considerations, such as patient or physician preference, ease of administra-
tion and cost.
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OBJECTIVES: No major clinical trial has compared rosuvastatin with atorvastatin
in preventing major adverse cardiovascular events (MACE). This study estimated
the effectiveness of rosuvastatin 20mg (R20) versus atorvastatin 40mg (A40) and
80mg (A80) in preventing MACE in several higher cardiovascular risk patient pop-
ulations using simulation. METHODS: The extensively validated and published
Archimedes model was used to simulate head-to-head clinical trials in several
populations [10-year Framingham risk score (FRS) 5%, FRS20%, EURO-SCORE
5, Diabetes, secondary prevention, and Acute Coronary Syndrome (ACS)] to esti-
mate the occurrence of MACE (comprising MI, stroke, and cardiovascular death)
over time. Patients (ages 45–70) based on the National Health and Nutrition Exam-
ination Survey were enrolled in trial simulations. Treatments were modeled and
validated using biomarker and outcomes data from published trials. RESULTS: The
number of patients in each arm ranged from 3,060 to 55,000, depending on the trial
population. R20 reduced MACE more than A40 or A80 in all scenarios, with higher
risk subgroups showing greater absolute benefit. In individual trial simulations, the
5 year relative risk (RR) of MACE for R20 versus A40 ranged from 0.90 to 0.92.
Similarly, the 5 year RR ofMACE for R20 versus A80 ranged from0.93 to 0.95. Similar
estimates were observed at 10 and 20 years. The 5-year number needed to treat
(NNT) to prevent one MACE event with R20 vs. A40 and A80 decreased consistently
with increasing baseline cardiovascular risk (for R20 vs. A40, NNT of 268 for FRS
5% and 55 for ACS). CONCLUSIONS: Themodel estimated that R20 lowers the risk
ofMACEmore thanA40 or A80.While simulationmodels cannot replace controlled
clinical trials, this study bridges gaps in the evidence and helps identify cohorts
that would benefit most from treatment with rosuvastatin rather than atorvasta-
tin.
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OBJECTIVES: Length of hospital stay (LOS) is a major cost component of hospital
budgets. Accurate prediction of LOS has become increasingly important for health
care systems, and reducing the LOS has the potential for large savings in the public
hospital system. This study aimed to assess the factors associated with prolonged
LOS of acute ischemic stroke taking into consideration demographic, risk factors,
and clinical signs that can be assessed at the time of admission. Particular atten-
tion is paid on the impact of previous medication use on LOS.METHODS: A retro-
spective cohort study of all acute ischemic stroke survivors attending a hospital in
Malaysia fromMay 1, 2008 to December 31, 2008. Long hospital stay was defined as
a stay greater than or equal to the median of LOS. Data included demographic
information, clinical information, risk factors, and previous medication use. SPSS
version 15was used for data analysis. RESULTS:Overall, 363 patients were studied.
The median (interquartile range) of LOS was 69 (45-111) hours. The independent
factors associatedwith prolonged LOSwere a history of atrial fibrillation (P 0.011),
patients with moderate and severe Glasgow Coma Scale (P  0.001), patients with
higher body temperature (P  0.015), patients with higher fasting or random blood
glucose (P  0.004), and patients without previous use of angiotensin converting
enzyme inhibitor medication (P  0.027). CONCLUSIONS: This study provided sci-
entific data for the factors that could hamper the discharge, particularly before
clinicians can evaluate the most effective, efficient, and acceptable methods of
managing patients with acute ischemic stroke. Moreover, these variables are po-
tentially preventable or treatable at admission time and would be ideal targets to
reduce the burden of illness and healthcare costs of ischemic stroke.
PCV25
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IN THE UNITED STATES AND CANADA
Rouleau A, Gobaux V, Guilhaume C, Yiou A, Milea D
Lundbeck SAS, Issy-les-Moulineaux, France
OBJECTIVES: Acute ischemic stroke (AIS) is a major public health concern and
among the leading causes of death and disability in western societies. The man-
agement of AIS and its long term evolution in the USA and Canada was assessed
through a literature search.METHODS: Medline was searched for the time period
1999-2010 to identify stroke cohorts and registries containing relevant data on AIS
management and/or long term evolution. Subsequently, a ranking process was
used to identify and select the most relevant references. RESULTS: A total of 680
referenceswere retrieved (581USA and 99 Canada). Publications frommore than 80
distinct cohorts/registries/databases were analyzed and a final selection led to the
identification of 43 publications for the USA and 25 for Canada. IS proportion
among all strokes ranged from 43%-90% in hospital cohorts. 24%-33% of all stroke
patients arrived at the hospital within 3 hour of symptom onset and rt-PA treat-
ment was received in 1.1%-14% of all AIS patients. The majority of patients, i.e.
82%-100% underwent a CT/MRI scanning. In general, hospital setting and care
characteristics were poorly documented and relatively few quality indicators of
stroke management were targeted. For long term evolution outcomes, mortality
was well documented (5%-17% 1 month, 17%-35% 3 months, 30%-37% 3 years,
37%-54% 5 years). AIS recurrence and cardiac events were described in few, mainly
USA, studies. There was a lack of data on disability (modified Rankin Scale) evolu-
tion after 3 months and studies on depression were scarce. CONCLUSIONS: Hos-
pital setting, characteristics of care, and long term evolution of disability are poorly
documented in American and Canadian registries. New cohort and registry studies
should specifically aim to generate real life data on ischemic stroke care that influ-
ence short and long-term clinical and associated economic outcomes.
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